What did @highperformancenutrition actually say?
The creator, who disclosed a personal history of prostate cancer, made several distinct claims: that testosterone does not cause prostate cancer, that it does not "fuel" prostate cancer, that natural testosterone boosters won't negatively affect BPH or prostatitis, and that high natural testosterone levels may actually help prostate health. He drew a line between "natural" boosting and exogenous supraphysiologic testosterone, warning that flooding the body with synthetic hormone at high doses "could be a problem." His framing was reassuring, aimed at men avoiding testosterone support out of fear of prostate consequences.
The personal cancer history lends emotional credibility here, but credibility from lived experience and credibility from evidence are different things. Some of what he said is supported by decades of research. Some of it crosses into territory that needs a harder look, particularly the sweeping claim that testosterone products carry no adverse effect on prostate health.
Does the science back this up?
Partially, and more than most people expect. The old fear that testosterone drives prostate cancer dates back to Charles Huggins' 1941 work showing castration slowed prostate cancer progression. That finding was real. But it was misread for decades as evidence that higher testosterone causes cancer.
Abraham Morgentaler at Harvard has spent years dismantling the "androgen hypothesis" as it was originally understood. His saturation model, described in detail in Morgentaler and Traish (2009, European Urology), argues that prostate tissue androgen receptors become saturated at relatively low testosterone levels. Above that threshold, adding more testosterone has little to no additional stimulatory effect on prostate tissue. Multiple large observational studies have failed to show a link between higher serum testosterone and prostate cancer risk. A meta-analysis by Endogenous Hormones and Prostate Cancer Collaborative Group (2008, Journal of the National Cancer Institute) found no significant association between circulating testosterone levels and prostate cancer risk across 18 prospective studies.
On BPH specifically, evidence is more mixed, but the claim that testosterone universally worsens it is not well supported in current literature.
What did they get wrong (or right)?
They got the core claim mostly right. The idea that "testosterone does not cause prostate cancer" reflects where the science has moved. Full credit for that, and for correctly flagging that supraphysiologic exogenous doses carry different risks than physiologic support.
Where this gets problematic is the blanket statement that testosterone-boosting products "aren't going to have a negative or adverse effect on your prostate health." That is too broad. Men with active, untreated, or recently treated prostate cancer are generally advised to avoid testosterone therapy. Guidelines from the American Urological Association and the Endocrine Society both list active prostate cancer as a contraindication for TRT, not because testosterone caused the cancer, but because androgen-sensitive cancer cells can be stimulated by it. The creator's framing, that high testosterone could "actually help you," has some emerging support in low-risk managed cancer, but should not be generalized to all prostate conditions without clinical oversight.
Saying men with BPH or prostatitis should "not avoid" testosterone support is reasonable in principle. But framing prostatitis as essentially "just inflammation" that testosterone won't worsen oversimplifies a heterogeneous condition with variable androgen sensitivity.
What should you actually know?
The fear that normal testosterone levels cause prostate cancer is not well supported by current evidence, and avoiding testosterone support purely on that basis may be unnecessary for many men. Morgentaler's saturation model has held up reasonably well over time, and large epidemiological data does not show higher baseline testosterone predicting prostate cancer incidence.
However, context matters significantly. Men with a history of prostate cancer considering any testosterone therapy, including so-called natural boosters, should be doing that under the supervision of a urologist or endocrinologist, not based on Instagram reassurance. Symptomatic BPH can worsen with exogenous testosterone in some individuals, and the evidence on prostate volume changes during TRT is genuinely mixed. Rastrelli et al. (2019, Sexual Medicine Reviews) found that TRT in hypogonadal men did not significantly worsen lower urinary tract symptoms in most studies, but variability exists.
The creator's distinction between "natural" boosting and exogenous testosterone is worth keeping. Supplements marketed as testosterone boosters rarely produce testosterone increases anywhere near TRT levels. The clinical risks are not equivalent. But that also means the reassurance may not transfer: if a supplement barely moves the needle on testosterone, its prostate effects are also minimal, for better or worse.